share_log

Oppenheimer Maintains Outperform on Bicycle Therapeutics, Maintains $48 Price Target

Benzinga ·  Aug 8 02:01  · Ratings

Oppenheimer analyst Jay Olson maintains Bicycle Therapeutics (NASDAQ:BCYC) with a Outperform and maintains $48 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment